Anti-scarring compositions comprising growth factor neutralizing antibodies
First Claim
Patent Images
1. A method of inhibiting scar tissue formation during the healing of wounds, comprising the steps of administering to a host suffering from tissue wounding a growth factor neutralizing antibody specific against a growth factor selected from the group consisting of TGF-β
-
1, TGF-β
2 and PDGF, wherein the antibody neutralizes the stimulation of macrophage infiltration, fibroblast migration, extracellular matrix synthesis or deposition by fibroblasts, in the wound area before the granulation phase in a dosage effective to reduce activity of the growth factor.
2 Assignments
0 Petitions
Accused Products
Abstract
A composition for use in the treatment of wounds to inhibit scar tissue formation during healing, comprising an effective amount of an activity-inhibiting growth factor neutralizing agent or agents specific against all TGF-β, except for TGF-β3, and PDGF, together with a pharmaceutically acceptable carrier. A method of preparing the composition and a method of administering the composition to a host suffering from tissue wounding is also disclosed.
-
Citations
28 Claims
-
1. A method of inhibiting scar tissue formation during the healing of wounds, comprising the steps of administering to a host suffering from tissue wounding a growth factor neutralizing antibody specific against a growth factor selected from the group consisting of TGF-β
-
1, TGF-β
2 and PDGF, wherein the antibody neutralizes the stimulation of macrophage infiltration, fibroblast migration, extracellular matrix synthesis or deposition by fibroblasts, in the wound area before the granulation phase in a dosage effective to reduce activity of the growth factor. - View Dependent Claims (2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
1, TGF-β
-
3. A method of inhibiting scar tissue formation during the healing of wounds, comprising the steps of administering to a host suffering from tissue wounding a growth factor neutralizing antibody specific against a growth factor selected from the group consisting of TGF-β
-
1, TGF-β
2 and PDGF, wherein the antibody neutralizes the stimulation of macrophage infiltration, fibroblast migration, extracellular matrix synthesis or deposition by fibroblasts, in the wound area during the granulation phase in a dosage effective to reduce activity of the growth factor. - View Dependent Claims (4, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
1, TGF-β
Specification